cardiology
Interventional cardiology

Rivaroxaban trial after TAVR stopped due to adverse events

A trial testing the use of rivaroxaban (Xarelto) after transcatheter aortic valve replacement (TAVR) has been halted following a raised risk of adverse events with the anticoagulant compared to patients receiving clopidogrel and aspirin. In a letter to healthcare professionals rivaroxaban manufacturer Bayer noted that back in August the data safety monitoring board had recommended ...

Already a member?

Login to keep reading.


OR
© 2021 the limbic